OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented an update on the positive results of OSE-279 in the Phase 1/2 clinical evaluation in advanced solid tumors at the 2024 ESMO Targeted Anticancer Therapies Congress (ESMO TAT) held in Paris, France (February 26 – 28, Abstract #368; FPN 30P). Silvia Comis, Head of Clinical Development and Regulatory Affairs of OSE Immunotherapeutics, comments: “We are very pleased to share this po